Johnson & Johnson(JNJ)
NASDAQ

Company Profile & Information

$253.04
3.07 (1.23%)

Company Profile

Business overview, scale, and footprint

Company NameJohnson & Johnson
Ticker SymbolJNJ
ExchangeNYQ
SectorHealthcare
IndustryDrug Manufacturers - General
Employees138,200
CEOMr. Joaquin Duato
Founded1886
HeadquartersNew Brunswick, NJ, United States
CountryUnited States
Websitejnj.com
Next Earnings DateJul 15, 2026

Business Overview

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Insider Transactions

Open-market activity and option exercises

Insider Activity Summary

Insider trading activity for Johnson & Johnson (JNJ) over the last 3 months consists of 56 total transactions. Among these, company executives and board members conducted 56 buys (totaling 1,724,182 shares) and 0 sells (totaling 0 shares). This activity resulted in a net change of 1,724,182 shares, reflecting net buying interest with an estimated net acquisitions value of $14.03M.

56 insider transactions found. Showing 10 of 56 transactions.

Show:entries
Insider NameRelation to CompanyShares ChangedPriceTransaction Date
WENGEL KATHRYN EChief Technology Officer10,000$2.41Jun 11, 2026
REED JOHN COfficer25,255$N/AMay 1, 2026
DECKER ROBERT JOfficer4,075$1.01Feb 27, 2026
SCHMID TIMOTHYOfficer1,322$0.32Feb 20, 2026
SCHMID TIMOTHYOfficer22,623$5.53Feb 18, 2026
SCHMID TIMOTHYOfficer29,554$2.74Feb 18, 2026
SWANSON JAMES DChief Technology Officer62,080$15.11Feb 17, 2026
BROADHURST VANESSAOfficer6,197$1.51Feb 17, 2026
WOLK JOSEPH JChief Financial Officer89,654$21.77Feb 17, 2026
REED JOHN COfficer53,931$13.11Feb 17, 2026
Page 1 of 6 (56 total transactions)